The IHC4 and CTS (a clinical treatment score based on clinico-pathological parameters), have been combined by Cuzick et al., to yield an overall prognostic score that may prove useful in predicting risk of recurrence in ER positive BC patients [7,9]. Here, ESR1 is linked to breast cancer.